|
|
| (28 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{STRUCTURE_1cii| PDB=1cii | SIZE=400| SCENE=Colicin/3domains/1 |right|CAPTION=Crystal structure of Colicin Ia, the first colicin to be identified, [[1cii]] }}
| | <StructureSection load='1cii' size='340' side='right' caption='Crystal structure of Colicin Ia, the first colicin to be identified, [[1cii]]. ' scene=''> |
| | |
| | __TOC__ |
| | |
| | ==Function== |
|
| |
|
| '''Colicins''' are a type of bacteriocin - peptide and protein antibiotics released by bacteria to kill other bacteria of the same species, in order to provide a competitive advantage for nutrient acquisition <ref> PMID: 16166536 </ref>. Bacteriocins are named after their species of origin; colicins are so-called because they are produced by <i>E. Coli</i><ref>PMID: 17347522 </ref>. Because of their narrow killing spectrum which focuses primarily on the species which has made the peptide (or occasionally closely related species<ref> PMID: 12423779 </ref>), bacteriocins are important in microbial biodiversity and the stable co-existence of the bacterial populations<ref> PMID: 11792831 </ref><ref>PMID: 12110887 </ref>. | | '''Colicins''' are a type of bacteriocin - peptide and protein antibiotics released by bacteria to kill other bacteria of the same species, in order to provide a competitive advantage for nutrient acquisition <ref> PMID: 16166536 </ref>. Bacteriocins are named after their species of origin; colicins are so-called because they are produced by <i>E. Coli</i><ref>PMID: 17347522 </ref>. Because of their narrow killing spectrum which focuses primarily on the species which has made the peptide (or occasionally closely related species<ref> PMID: 12423779 </ref>), bacteriocins are important in microbial biodiversity and the stable co-existence of the bacterial populations<ref> PMID: 11792831 </ref><ref>PMID: 12110887 </ref>. |
|
| |
|
| Colicin peptides are plasmid-encoded. The peptide is released by the cell into the area surrounding it, and then parasitises proteins present in the host cell membrane to translocate across into the host cell. Many protein-protein interactions are involved in the cell entry, and the main system is involved in the grouping of colicins into two families: Group A colicins use the [[Tol]] system to enter the host cell, and Group B use the [[Ton]] system. Once inside the host cell, the cell killing follows 1st order kinetics - ie one molecule is theoretically sufficient to kill the cell<ref> PMID: 7577966 </ref>. | | Colicin peptides are plasmid-encoded. The peptide is released by the cell into the area surrounding it, and then parasitises proteins present in the host cell membrane to translocate across into the host cell. Many protein-protein interactions are involved in the cell entry, and the main system is involved in the grouping of colicins into two families: Group A colicins use the [[Tol]] system to enter the host cell, and Group B use the [[Ton]] system. Once inside the host cell, the cell killing follows 1st order kinetics - ie one molecule is theoretically sufficient to kill the cell<ref> PMID: 7577966 </ref>. |
| | *'''Colicin-A''' see [[Colicin-A]] |
| | *'''Colicin-B''' forms small, ion-permeable channels. It inhibits the transport of Pro and enhances the transport of methylglucoside<ref> PMID:2419320 </ref>. |
| | *'''Colicin-D''' cleaves the anticodon loop of tRNAArg<ref> PMID:15014439 </ref> |
| | *'''Colicin-E1''' binds to TolC and plug channels of Gram-negative bacteria<ref> PMID:35199644 </ref> |
| | *'''Colicin-E2''' and '''Colicin-E9''' bind to BtuB and cleaves the target DNA<ref> PMID:17416663 </ref>, <ref> PMID:15995205 </ref> |
| | *'''Colicin-E3''' cleaves the ribosome A site<ref> PMID:11741540 </ref> |
| | *'''Colicin-E5''' cleaves tRNA which contain the nucleotide queuosine<ref> PMID:16060658 </ref> |
| | *'''Colicin-E7''' binds to immunity protein 7<ref> PMID:10368275 </ref> |
| | *'''Colicin-Ia''' see [[Colicin-Ia]] |
| | *'''Colicin-M''' cleaves peptidoglycans by hydrolysing their phosphoester bonds<ref> PMID:23176510 </ref> |
|
| |
|
| The structure of all colicins, of which over 20 have been identified, follows a 3 domain design: | | The structure of all colicins, of which over 20 have been identified, follows a 3 domain design: |
| Line 14: |
Line 28: |
| *[[Pore Formation]]<br /> | | *[[Pore Formation]]<br /> |
| *[[Translocation domain]]<br /> | | *[[Translocation domain]]<br /> |
| *[[Colicin A]]<br /> | | *[[H-N-H motif]]<br /> |
| *[[16s rRNase activity]]. | | *[[16s rRNase activity]]<br /> |
| | *[[Cloacin DF13]]. |
| | *[[Colicin Immunity Protein]] |
|
| |
|
| ==Synthesis, Production and Release== | | ==Synthesis, Production and Release== |
| Line 105: |
Line 121: |
| Table taken from <ref>PMID: 21060316 </ref> except where indicated. | | Table taken from <ref>PMID: 21060316 </ref> except where indicated. |
|
| |
|
| ==Directed evolution and Colicin7/Immunity-proteins complexes<ref>PMID:19749752</ref>== | | ==3D structure of Colicin== |
| <StructureSection load='3gkl' size='500' frame='true' align='right' scene='3gkl/Al/1' >
| | [[Colicin 3D structures]] |
| Iterative rounds of random mutagenesis and selection of <span style="color:yellow;background-color:black;font-weight:bold;">immunity protein 9 (colored yellow)</span> toward higher affinity for ColE7, and selectivity (against ColE9 inhibition), led to significant increase in affinity and selectivity. Several evolved variants were obtained. The crystal structures of the two final generation <scene name='3gkl/Al/3'>variants</scene> <span style="color:lime;background-color:black;font-weight:bold;">R12-2</span> ('''3gkl'''; T20A, N24D, T27A, S28T, V34D, V37J, E41G, and K57E) and <font color='darkred'><b>R12-13</b></font> ([[3gjn]]; N24D, D25E, T27A, S28T, V34D, V37J, and Y55W) in complex with ColE7 were solved.
| |
|
| |
|
| {{Clear}}
| |
| <scene name='3gkl/Align/2'>Structural alignment</scene> of the immunity protein 9 (Im9, [[1bxi]], <span style="color:yellow;background-color:black;font-weight:bold;">colored yellow</span>), <span style="color:lime;background-color:black;font-weight:bold;">evolved variant R12-2 (lime)</span>, and <font color='blue'><b>immunity protein 7 (Im7, colored blue</b></font>, [[7cei]]) reveals their structural identity. However, when the immunity proteins-bound <scene name='3gkl/Align/3'>colicins within their complexes were aligned</scene>, they demonstrate somewhat different picture. The Im9 and Im7 are differ more in their binding configurations (19°, with Tyr54-Tyr55 as the pivot), while the variant R12-2 is in an intermediate configuration between Im9 and Im7. Of note, in the variant R12-2 (3gkl) and Im9 ([[1bxi]]) there are Tyr54 and Tyr55, while in the Im7 ([[7cei]]) Tyr55 and Tyr56 are homologous to them. The most <scene name='3gkl/Align/4'>prominent differences</scene> are in the loop between helices α1 and α2 in Im9 (yellow, labeled in black) and <span style="color:lime;background-color:black;font-weight:bold;">evolved variant R12-2 (lime, labeled in black)</span>. This loop consists of three mutations: N24D, T27A, and S28T in variant R12-2. We can see the deviations in the relative position of helices α1 and α2, in the loop's backbone and in the side chains of residues 24, 26 and 28.
| |
|
| |
| {{Clear}}
| |
| Comparison of the different Im-colicin complexes reveals changes in the binding configuration of the evolved variants which increase affinity toward ColE7 by re-aligning pre-existing Im9 residues. Glu30 of Im9 ([[1bxi]], <span style="color:yellow;background-color:black;font-weight:bold;">colored yellow</span>) forms <scene name='3gkl/Active_site/3'>double salt bridge</scene> with Arg54 of <span style="color:orange;background-color:black;font-weight:bold;">ColE9 (orange)</span>, whereas Asp51 have not direct side chain–side chain interactions. <font color='blue'><b>Asp31 of Im7 (blue)</b></font> which is corresponding to Im9 Glu30 is involved in <scene name='3gkl/Active_site/6'>cluster of salt bridge bonds</scene> to <font color='darkmagenta'><b>Arg520 and Lys525 of ColE7 (darkmagenta)</b></font>, while <font color='blue'><b>Asp52 of Im7</b></font> (corresponding to Im9 Asp51) is within hydrogen bond distance to <font color='darkmagenta'><b>Thr531 and Arg530 of ColE7</b></font> ([[7cei]]). <span style="color:lime;background-color:black;font-weight:bold;">Glu30 in the variant R12-2 (lime)</span> is shifted and forms a <scene name='3gkl/Active_site/8'>double salt bridge</scene> to <font color='magenta'><b>Arg520 of ColE7 (magenta)</b></font>. <span style="color:lime;background-color:black;font-weight:bold;">Asp51</span> is within hydrogen bond distance to <font color='magenta'><b>Thr531 of ColE7</b></font> ([[3gkl]]). However, the side chains of <font color='magenta'><b>Lys525 and Arg530</b></font>, which are very important in salt bridge contacts with Glu30 and Asp51, respectively, in the structure of the ColE7–Im7 complex have a different conformation that eliminates these contacts in evolved variant R12-2.
| |
|
| |
| {{Clear}}
| |
| In the <scene name='3gkl/Mut/2'>Im9</scene> <font color='magenta'><b>Val37 (colored magenta)</b></font> forms stabilizing hydrogen bond with Leu33. In the <scene name='3gkl/Mut/3'>evolved variant R12-2</scene>, <font color='darkmagenta'><b>Ile37 (colored darkmagenta)</b></font> interacts with two additional residues, Tyr54 and Ser50. Moreover, <font color='darkmagenta'><b>Ile37</b></font> also forms additional hydrogen bond with Gly41 and can thereby have enabled the appearance of the selectivity mutation E41G.
| |
| {{Clear}}
| |
|
| |
| In contrast to the <span style="color:lime;background-color:black;font-weight:bold;">evolved variant R12-2</span> ([[3gkl]]), the <span style="color:cyan;background-color:black;font-weight:bold;">evolved variant R12-13</span> ([[3gjn]]) carries the <scene name='3gkl/Align/10'>Tyr55Trp mutation</scene> in the conserved region. Both <span style="color:lime;background-color:black;font-weight:bold;">Tyr55 in R12-2</span> and <span style="color:cyan;background-color:black;font-weight:bold;">Trp55 in R12-13</span> could sustain the
| |
| hydrophobic core and create a <scene name='3gkl/Align/11'>hydrogen bond</scene> to Lys528 backbone ([[3gkl]] colicin residues are colored in <font color='magenta'><b>magenta</b></font>, 3gjn colicin residues are colored <font color='blueviolet'><b>blueviolet</b></font>). However, the additional bulkiness of the Trp contributes in expanding its <scene name='3gkl/Align/9'>hydrophobic interactions</scene> to Phe541 and Phe513 also leading to the small shift in the alkyl chain of Arg530.
| |
| {{Clear}}
| |
|
| |
| The <scene name='3gkl/Ali/1'>overall conformation</scene> of the two evolved variants <span style="color:lime;background-color:black;font-weight:bold;">R12-2</span> ([[3gkl]]) and <span style="color:cyan;background-color:black;font-weight:bold;">R12-13</span> ([[3gjn]]) is very similar. The variant <span style="color:lime;background-color:black;font-weight:bold;">R12-2</span> carries <scene name='3gkl/Ali/2'>mutation E41G</scene>. In the <span style="color:yellow;background-color:black;font-weight:bold;">bound wildtype Im9 (yellow)</span> Glu41 makes a <scene name='3gkl/Ali/3'>salt bridge</scene> with the <span style="color:orange;background-color:black;font-weight:bold;">ColE9’s</span> Lys97 ([[1bxi]]). While in the <font color='blueviolet'><b>R12-13</b></font>/<span style="color:cyan;background-color:black;font-weight:bold;">ColE7</span> complex the <font color='blueviolet'><b>closest ColE7 residues</b></font> <scene name='3gkl/Ali/4'>contacting</scene> <span style="color:cyan;background-color:black;font-weight:bold;">R12-13 Glu41</span> are <font color='blueviolet'><b>Thr531 (3.37Å) and Lys528 (8.85Å)</b></font> ([[3gjn]]). In the <span style="color:lime;background-color:black;font-weight:bold;">R12-2</span>/<font color='magenta'><b>ColE7</b></font> complex the <scene name='3gkl/Ali/5'>closest</scene> <font color='magenta'><b>ColE7 residue</b></font> to <span style="color:lime;background-color:black;font-weight:bold;">R12-2 Gly41</span> is <font color='magenta'><b>Thr531 (9.48Å)</b></font> ([[3gkl]]).
| |
| {{Clear}}
| |
| </StructureSection> | | </StructureSection> |
|
| |
|
| |
| ==3D structure of Colicin==
| |
|
| |
| ''Update June 2012''
| |
|
| |
| ===Colicin-A===
| |
|
| |
| [[3iax]], [[3qdr]] – CfColA translocation domain + EcTolB – ''Citrobacter freundii''<br />
| |
| [[1col]] – EcColA pore-forming domain
| |
|
| |
| ===Colicin-B===
| |
|
| |
| [[1rh1]] - EcColB
| |
|
| |
| ===Colicin-D===
| |
|
| |
| [[1tfk]], [[1tfo]], [[1v74]] - EcColD catalytic domain + EcColD immunity protein<br />
| |
|
| |
| ===Colicin-E1===
| |
|
| |
| [[2i88]] – EcColE1 channel-forming domain
| |
|
| |
| ===Colicin-E2===
| |
|
| |
| [[2ysu]] – EcColE2 receptor-binding domain + BtuB
| |
|
| |
| ===Colicin-E3===
| |
|
| |
| [[2xfz]], [[2xg1]] – EcColE3 cytotoxic domain (mutant) + Tt30S ribosome – ''Thermos thermophilus''<br />
| |
| [[2zld]] - EcColE3 cytotoxic domain + outer membrane protein F<br />
| |
| [[1jch]] – EcColE3 + EcColE3 immunity protein<br />
| |
| [[2b5u]] – EcColE3 (mutant) + EcColE3 immunity protein<br />
| |
| [[1e44]] – EcColE3 nuclease domain + EcColE3 immunity protein<br />
| |
| [[1ujw]] – EcColE3 receptor-binding domain + BtuB
| |
|
| |
| ===Colicin-E5===
| |
|
| |
| [[2djh]], [[3ao9]] – EcColE5 C-terminal domain<br />
| |
| [[3vj7]] - EcColE5 C-terminal domain (mutant)<br />
| |
| [[2a8k]] – EcColE5 catalytic domain<br />
| |
| [[2dfx]] – EcColE5 C-terminal domain + EcColE5 immunity protein<br />
| |
| [[2fhz]] – EcColE5 residues 74-180 + EcColE5 immunity protein<br />
| |
|
| |
| ===Colicin-E7===
| |
|
| |
| [[1unk]] - EcColE7<br />
| |
| [[2axc]] - EcColE7 translocation domain<br />
| |
| [[1m08]] - EcColE7 nuclease domain<br />
| |
| [[3fbd]], [[1zns]], [[2ivh]] – EcColE7 (mutant) + DNA<br />
| |
| [[1pt3]] - EcColE7 nuclease domain + DNA<br />
| |
| [[1mz8]], [[7cei]] - EcColE7 nuclease domain + EcColE7 immunity protein<br />
| |
| [[3gjn]] - EcColE7 nuclease domain + EcColE9 immunity protein (mutant) <br />
| |
| [[3gkl]] - EcColE7 nuclease domain (mutant) + EcColE9 immunity protein (mutant) <br />
| |
| [[2jaz]], [[2jb0]], [[2jbg]], [[1znv]] - EcColE7 nuclease domain (mutant) + EcColE7 immunity protein<br />
| |
| [[2erh]], [[1ujz]] - EcColE7 (mutant) + EcColE7 immunity protein (mutant)
| |
|
| |
| ===Colicin-E9===
| |
|
| |
| [[1fsj]] - EcColE9 DNase domain<br />
| |
| [[1v13]] - EcColE9 DNase domain (mutant) <br />
| |
| [[1v14]], [[1v15]] - EcColE9 DNase domain (mutant) + DNA<br />
| |
| [[2wpt]] – EcColE9 (mutant) + EcColE2 immunity protein<br />
| |
| [[2k5x]], [[1emv]], [[1bxi]] – EcColE9 DNase domain + EcColE9 immunity protein<br />
| |
| [[2vln]], [[2vlo]], [[2vlp]], [[2vlq]] - EcColE9 DNase domain (mutant) + EcColE9 immunity protein<br />
| |
| [[2gze]], [[2gzg]], [[2gzi]], [[2gzj]], [[2gzf]], [[2gyk]], [[1fr2]] - EcColE9 DNase domain + EcColE9 immunity protein (mutant)<br />
| |
| [[2ivz]] - EcColE9 T domain + TolB<br />
| |
| [[3o0e]] - EcColE9 fragment + outer membrane porin 1A
| |
|
| |
| ===Colicin-Ia===
| |
|
| |
| [[1cii]] - EcColIa<br />
| |
| [[2hdi]] – EcColIA R domain + ColI receptor
| |
|
| |
| ===Colicin-M===
| |
|
| |
| [[2xmx]], [[3da3]], [[3da4]] – EcColM<br />
| |
| [[2xtq]], [[2xtr]] – EcColM (mutant)
| |
|
| |
| ===Colicin-N===
| |
|
| |
| [[1a87]] – EcColN receptor-binding domain
| |
|
| |
| ===Colicin-S4===
| |
|
| |
| [[3few]] – EcColS4
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| ==References== | | ==References== |